Research Analysts Set Expectations for CorMedix Q2 Earnings

CorMedix Inc. (NASDAQ:CRMD) – Investment analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for CorMedix in a research note issued on Tuesday, May 6th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn $0.14 per share for the quarter, up from their prior estimate of $0.05. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for CorMedix’s Q4 2025 earnings at $0.12 EPS, FY2026 earnings at $2.03 EPS, FY2027 earnings at $2.65 EPS and FY2028 earnings at $3.13 EPS.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Tuesday, May 6th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.05. The business had revenue of $39.08 million for the quarter, compared to the consensus estimate of $38.90 million. During the same period in the prior year, the business posted ($0.25) EPS.

A number of other brokerages also recently issued reports on CRMD. Needham & Company LLC boosted their price objective on shares of CorMedix from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday. Leerink Partners initiated coverage on CorMedix in a report on Friday, March 7th. They issued an “outperform” rating and a $18.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $12.00 price target on shares of CorMedix in a report on Wednesday, March 26th. StockNews.com upgraded shares of CorMedix from a “sell” rating to a “hold” rating in a research report on Tuesday, April 1st. Finally, D. Boral Capital restated a “buy” rating and set a $15.00 price objective on shares of CorMedix in a report on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $15.00.

CorMedix Stock Down 3.1 %

Shares of NASDAQ CRMD opened at $11.66 on Friday. The company has a market cap of $790.66 million, a PE ratio of -14.39 and a beta of 1.54. The firm’s 50-day moving average price is $8.73 and its 200-day moving average price is $9.75. CorMedix has a 52-week low of $3.61 and a 52-week high of $13.85.

Hedge Funds Weigh In On CorMedix

A number of hedge funds and other institutional investors have recently modified their holdings of CRMD. Vanguard Group Inc. boosted its position in CorMedix by 7.9% during the 1st quarter. Vanguard Group Inc. now owns 3,646,551 shares of the company’s stock valued at $22,463,000 after acquiring an additional 268,360 shares in the last quarter. Elliott Investment Management L.P. lifted its stake in shares of CorMedix by 85.1% during the 4th quarter. Elliott Investment Management L.P. now owns 2,870,632 shares of the company’s stock worth $23,252,000 after purchasing an additional 1,320,109 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of CorMedix by 8.4% during the 4th quarter. Geode Capital Management LLC now owns 1,392,820 shares of the company’s stock worth $11,284,000 after purchasing an additional 108,356 shares during the last quarter. Northern Trust Corp grew its stake in CorMedix by 14.4% in the fourth quarter. Northern Trust Corp now owns 511,565 shares of the company’s stock valued at $4,144,000 after purchasing an additional 64,243 shares during the last quarter. Finally, J. Goldman & Co LP raised its holdings in CorMedix by 221.1% in the fourth quarter. J. Goldman & Co LP now owns 457,320 shares of the company’s stock worth $3,704,000 after purchasing an additional 314,880 shares in the last quarter. 34.18% of the stock is currently owned by institutional investors.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.